Picture of Gilead Sciences logo

GILD Gilead Sciences Share Price

0.000.00%
us flag iconLast trade - 00:00
HealthcareConservativeLarge CapContrarian

Momentum

Relative Strength (%)
1m-3.59%
3m-16.85%
6m-19.78%
1yr-30.06%
Volume Change (%)
10d/3m+10.11%
Price vs... (%)
52w High-17.36%
50d MA-4.72%
200d MA-6.1%

Growth & Value

12m Forecast RollingIndustryMarket
PE Ratio (f)10.13
PEG Ratio (f)0.41
EPS Growth (f)33.2%
Dividend Yield (f)4.36%
Valuation (ttm)IndustryMarket
Price to Book Value3.96
Price to Tang. Bookn/a
Price to Free Cashflow12.19
Price to Sales3.34
EV to EBITDA10.5

Shareholder Activity

TypeBuy / Hold / Sell
Institutions
Directors
Community

Guru Screens

Quality

NameIndustryMarket
Return on Capital14.96%
Return on Equity25.71%
Operating Margin28.05%

Financial Summary

Year End 31st DecUnit201920202021202220232024E2025ECAGR / Avg
Total Revenue$m22,44924,68927,30527,28127,11627,498.4528,039.324.15%
Operating Profitm
Net Profitm
EPS Reported
Diluted Normalised EPS
EPS Growth%+0.93-97.74+4964.84+7.83-8.28+45.39+4.71n/a
PE Ratiox
PEG
Profitability
Operating Margin%
ROA%
ROCE%
ROE%
Cashflow
Op. Cashflow ps
Capex ps
Free Cashflow ps
Dividends
Dividend ps
Dividend Growth%
Dividend Yield%
Dividend Coverx
Balance Sheet
Cash etcm
Working Capitalm
NFAm
Net Debtm
Book Valuem
Diluted Weighted Average Sharesm
Book Value ps

Health Trend(F-Score)

12345678910

Bankruptcy Score(Z-Score)

Distress
Cautious
Safe

Earnings Manipulation Risk(M-Score)

Other Ratios

Leverage (ttm)Total- Intang+ Pension
Gross Gearing
Net Gearing
Cash / Assets

Recent History

Latest interim period vs. prior periodIndustryMarket
Sales Growth
EPS Growth
3yr Compound Annual Growth RateIndustryMarket
Sales CAGR
EPS CAGR
DPS CAGR

Graphical History

Revenue
Blurred out image of Revenue chart
Net Income
Blurred out image of Net Income chart
Normalised EPS
Blurred out image of Normalised EPS chart
PE Ratio Range
Blurred out image of PE Ratio Range chart
Dividend Yield Range
Blurred out image of Dividend Yield Range chart

Analyst Forecasts

Price target
( price)
31st Dec 202431st Dec 2025
Est. Long Term Growth Rate: Net Profit
()
EPS
()
DPS
()
Net Profit
()
EPS
()
DPS
()
Consensus Estimate
1m Change
3m Change

Analyst Consensus

Strong SellSellHoldBuyStrong Buy

EPS 2024 / 2025

Blurred out image of Gilead Sciences EPS forecast chart

Profile Summary

Gilead Sciences, Inc. is a biopharmaceutical company. It is engaged in advancing medicines to prevent and treat life-threatening diseases, including human immunodeficiency virus (HIV), viral hepatitis, coronavirus disease 2019 (COVID-19) and cancer. It is focused on the discovery, development and commercialization of medicines in areas of unmet medical need. Its portfolio of marketed products includes AmBisome, Atripla, Biktarvy, Cayston, Complera, Descovy, Descovy for PrEP, Emtriva, Epclusa, Eviplera, Genvoya, Harvoni, Hepcludex, Hepsera, Jyseleca, Letairis, Odefsey, Sovaldi, Stribild, Sunlenca, Tecartus, Trodelvy, Truvada, Truvada for PrEP, Tybost, Veklury, Vemlidy, Viread, Vosevi, Yescarta and Zydelig. Its product candidates include Bulevirtide, Lenacapavir, Axicabtagene ciloleucel, and Domvanalimab and zimberelimab, and seladelpar. Seladelpar shall be used for the treatment of primary biliary cholangitis (PBC), including pruritus. The Company operates in more than 35 countries.

Directors

Last Annual
December 31st, 2023
Last Interim
December 31st, 2023
Incorporated
June 22nd, 1987
Public Since
January 22nd, 1992
No. of Shareholders
1,396
No. of Employees
18,000
Sector
Pharmaceuticals
Industry
Healthcare
Exchange
us flag iconNASDAQ Global Select Market
Shares in Issue
1,245,774,616

GILD Share Price Performance

Upcoming Events for GILD

Q1 2024 Gilead Sciences Inc Earnings Release

Gilead Sciences Inc Annual Shareholders Meeting

Gilead Sciences Inc Annual Shareholders Meeting

Q2 2024 Gilead Sciences Inc Earnings Release

Similar to GILD

Picture of Amgen logo

Amgen

us flag iconNASDAQ Global Select Market

Picture of Amphastar Pharmaceuticals logo

Amphastar Pharmaceuticals

us flag iconNASDAQ Global Select Market

Picture of Amylyx Pharmaceuticals logo

Amylyx Pharmaceuticals

us flag iconNASDAQ Global Select Market

Picture of Anika Therapeutics logo

Anika Therapeutics

us flag iconNASDAQ Global Select Market

Picture of Annexon logo

Annexon

us flag iconNASDAQ Global Select Market

FAQ